CD4 and melanoma: In murine models of melanoma, β‐emitting TRT has been shown to trigger the release of damage‐associated molecular patterns (DAMPs) [15, 16], promote the recruitment of immune cells—including CD4+ and CD8+ T cells [17, 18], as well as NK cells [16]—and potentially enhance tumour immunogenicity.